Seely Lynn
Lyell Immunopharma, Inc. · President and CEO
Seely Lynn is listed in filings as President and CEO at Lyell Immunopharma, Inc.. This profile follows SEC Form 4 activity through Feb 12, 2026, including sale activity and purchase activity. Recent filings connect the profile to Lyell Immunopharma, Inc. (LYEL) and Blueprint Medicines Corporation (BPMC). The current snapshot covers public activity from Feb 26, 2025 to Feb 12, 2026. Reported amounts are shown as $174.4K to $10.1K. The page organizes purchases, sales, issuer links, reported share activity, and filing evidence for review as public disclosure data.
History Trades
| Company | Value | Action | Price | Last Price |
|---|---|---|---|---|
| $10k438 shares | SellFeb 10, 2026 | $23.12 | $12.74 | |
| $6.6k412 shares | SellNov 10, 2025 | $16.11 | $12.74 | |
| $77k7.3k shares | SellAug 21, 2025 | $10.54 | $12.74 | |
| $4.2k406 shares | SellAug 12, 2025 | $10.34 | $12.74 | |
| $4.1k391 shares | SellAug 11, 2025 | $10.53 | $12.74 | |
| $106k175k shares | BuyMar 14, 2025 | $0.6068 | $12.74 |